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Background: Our ongoing research has revealed that total saponins extracted from the medicinal herb Radix
Astragali (AST) exhibits significant growth-inhibitory and proapoptotic effects in human cancer cells. In the present
study, the potential of AST in controlling angiogenesis was further investigated with elaboration of the underlying
molecular mechanism in human colon cancer cell and tumor xenograft.
Results: AST decreased the protein level of VEGF and bFGF in HCT 116 colon cancer cells in a time- and
dose-dependent manner. Among the Akt/mTOR signal transduction molecules being examined, AST caused PTEN
upregulation, reduction in Akt phosphorylation and subsequent activation of mTOR. AST also suppressed the
induction of HIF-1α and VEGF under CoCl2-mimicked hypoxia. These effects were intensified by combined
treatment of AST with the mTOR inhibitor rapamycin. Despite this, our data also indicate that AST could attenuate
cobalt chloride-evoked COX-2 activation, while such effect on COX-2 and its downstream target VEGF was
intensified when indomethacin was concurrently treated. The anti-carcinogenic action of AST was further illustrated
in HCT 116 xenografted athymic nude mice. AST significantly suppressed tumor growth and reduced serum VEGF
level in vivo. In the tumor tissues excised from AST-treated animals, protein level of p-Akt, p-mTOR, VEGF, VEGFR1
and VEGFR2 was down-regulated. Immunohistochemistry has also revealed that AST effectively reduced the level of
COX-2 in tumor sections when compared with that in untreated control.
Conclusion: Taken together, these findings suggest that AST exerts anti-carcinogenic activity in colon cancer cells
through modulation of mTOR signaling and downregulation of COX-2, which together reduce VEGF level in tumor
cells that could potentially suppress angiogenesis.
Keywords: Astragalus saponins, Hypoxia, VEGF, Akt/mTOR, COX-2, Colon cancerBackground
Epidemiological studies have suggested that herbal medi-
cines and fruit extracts play a major role in the preven-
tion and treatment of many types of cancer including
that of the colon [1-3]. Radix Astragali is frequently used
as health food supplement in Asian population and also
serves as a lead herb in many Traditional Chinese Medi-
cine formulations. Total Astragalus saponins (AST) are
the major active constituent found in this herb and its
anti-cancer effects have been investigated for some times.
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reproduction in any medium, provided the orthat AST could exert cell growth inhibition in various
cancer cell lines through regulation of cell proliferation
and apoptosis [4,5]. AST also possesses prominent effects
against colon cancer growth in HT-29 nude mice tumor
xenograft with much fewer adverse effects compared to
conventional chemotherapeutic drugs [5]. Recently, we
found that AST could also reduce cell invasiveness and
angiogenesis in gastric cancer cells [6]. In this study, we
attempted to explore the possible anti-angiogenic effects
of AST in colon cancer and to unveil the underlying
mechanism.
Angiogenesis is essential for the initiation, progression
and metastasis of solid tumor. Overexpression of angio-
genic factors can direct the endothelial cell proliferation
and sprouting in tumor mass as well as maintain. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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endothelial growth factor (VEGF) has been identified as
the most important angiogenic factor for tumor progres-
sion because it is released by a variety of tumor cells and
overexpresses in different human cancers. Drugs that
can inhibit the production of VEGF or block its receptor
signaling show significant inhibition of tumor growth [8-
10]. Bevacizumab, a recombinant human monoclonal
antibody directed against VEGF, has shown promising
effects when used as combination therapy in advanced
colorectal cancer patients [11].
Intra-tumoral hypoxia is a common phenomenon as
the rapid growing cells deplete oxygen in the cellular
microenvironment. A series of adaptive responses will
be triggered, which involves the elevation of the tran-
scription and subsequent translation of genes respon-
sible for cell survival, glucose metabolism, angiogenesis
and invasion [12]. Activation of hypoxia-inducible fac-
tor-1 alpha (HIF-1α) plays a major role in the develop-
ment of tumor phenotype, especially in aggressive
tumors [13]. Induction of VEGF expression promotes
angiogenesis, which is mediated primarily through HIF-
1α [14,15]. Under hypoxic condition, the ubiquitination
of HIF-1α is inhibited and its accumulation transcrip-
tionally activates VEGF gene by binding to a hypoxia re-
sponsive element (HRE) of the VEGF promoter [12].
Development of drugs targeting on the HIF system and
VEGF is currently under active investigation in order to
establish a target-oriented cancer therapy [16].
Cyclooxygenase-2 (COX-2), which is originally found
to be an inflammatory mediator and a key rate-
limiting enzyme in prostaglandins (PGs) production, is
overexpressed at multiple stages of colon carcinogen-
esis. The role of COX-2 in tumor angiogenesis has
been established since emerging evidence showed that
inhibition of this pathway reduced tumor growth by
suppressing VEGF expression and formation of blood
vessels [17]. It was also found that COX-2 is a direct
target gene of HIF-1 in colon cancer cells. The overex-
pression of COX-2 in physical-stimulated or chemical-
induced hypoxia enhanced VEGF production, which
was accompanied by upregulation of PGE2 level in sev-
eral human cancer cell lines [18,19]. NSAID, either
COX-2 selective or nonselective, can block angiogen-
esis induced by co-cultured colon cancer cells [20].
The phosphatidylinositol 3’-kinase p85α (PI3K) gene is
an oncogene in human ovarian and colon tumors [21].
PI3K/Akt/mTOR cascade is one of the growth factor-
dependent signaling pathways modulating the ampli-
tude of HIF-1α activation [22,23]. PI3K phosphorylates
phosphatidylinositol-4,5-bis- phosphate (PIP2) to form
phosphatidylinositol-4,5-triphosphate (PIP3), and such
conversion can be blocked by the tumor suppressor
gene PTEN. Activated PI3K recruits downstreammolecule Akt, followed by activation of the mamma-
lian target of rapamycin (mTOR). Apart from regulat-
ing cell growth and development [24], mTOR signaling
has also attributed to angiogenesis through the induc-
tion of VEGF along with its receptor, both mediated
by the increase of HIF-1α under hypoxic condition
[25]. Interestingly, mTOR pathway was involved in the
suppression of cell growth by COX-2 inhibitor in colo-
rectal cancer [26], and the anti-angiogenic effect of
mTOR inhibitor was in turn mediated by COX-2 in
Ewing sarcoma [27].
The present study aimed at investigating the potential
anti-angiogenic effect of AST in colon cancer, by exam-
ining the modulation of hypoxia-inducible HIF-1α and
VEGF and the involving signaling pathways.
Methods
Extraction of Astragalus saponins (AST) and induction of
hypoxia
Radix Astragalus membranaceus (Fisch.) Bunge var.
mongolicus was obtained from the province of Shanxi,
China. Total Astragalus saponins extract was prepared
as described previously [5]. In brief, the herb was
refluxed with 2% potassium hydroxide in methanol for
1 h. The solvent was evaporated and reconstituted with
water. Butan-1-ol was then added for phase separation.
Total saponins (AST) obtained were lyophilized into dry
powder (about 0.6% w/w) and dissolved in ultrapure
water to form a 10 mg/ml stock. To mimic a hypoxic
condition, cells were treated with 100 μM cobalt chlor-
ide (CoCl2) 30 min prior to various drug treatments.
The concentrations of AST being used in the in vitro
study were chosen based on our findings from previous
studies [4].
Cell culture
Human colon adenocarcinoma cell lines HCT 116 and
HT-29 were obtained from American Type Culture Col-
lection (Manassa, VA) and cultured in Dulbecco’s Modi-
fied Essential Medium (DMEM) supplemented with 10%
fetal bovine serum (FBS) plus 1% penicillin and strepto-
mycin. Cultures were maintained in a humidified incu-
bator with 5% CO2 at 37°C. All chemicals used for cell
culture were purchased from Gibco (Carlsbad, CA).
Antibodies and reagents
Rapamycin and LY 294002 were purchased from Merck
(Whitehouse Station, NJ). Sources of antibodies are as
follows: bFGF (BD Pharmingen, San Jose, CA); p-Akt
(Ser 473), Akt, p-JNK, total JNK, p-mTOR, mTOR, p-
p38 and total p38 (Cell Signaling Technology, Danvers,
MA); β-actin (Sigma-Aldrich, St Louis, MO); HIF-1α,
PTEN, VEGF, VEGFR1 and VEGFR2 (Santa Cruz Bio-
technology, Santa Cruz, CA); COX-2 (Thermo Fisher
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HRP-conjugated secondary antibody (Zymed Laborator-
ies, San Francisco, CA). Other chemicals were obtained
from Sigma-Aldrich (St. Louis, MO) unless specified. All
reagents used for RT-PCR were purchased from Invitro-
gen (Carlsbad, CA).
Western immunoblotting
Cells or tumor tissues were lysed in RIPA buffer con-
taining 50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5%
deoxycholate, 2 mM EDTA, 0.1% Triton X-100, 10%
glycerol, 1 mM phenylmethylsulfonyl fluoride and
10 μg/ml aprotinin. The extracted protein was quanti-
fied using CoomassieW plus Protein Assay Reagent kit
(Pierce, Rockford, IL). Total cellular proteins were sepa-
rated by 8-15% SDS polyacrylamide gel electrophoresis.
The proteins on the gel were transferred onto a nitro-
cellulose membrane (0.45 μm) and then probed with
the respective primary antibodies, followed by the
addition of the corresponding HRP-conjugated second-
ary antibodies. The immunoblots were visualized with
enhanced chemiluminescence (ECL) reagents (Amer-
sham Biosciences, Piscataway, NJ) and exposed to X-ray
film. The membranes were then reprobed with β-actin
for normalization. The band density on the film was
analyzed by the Quantity One version 4.4.1 Basic Soft-
ware (BioRad, Hercules, CA). In addition to representa-
tive bands, relative band densities (as arbitrary data)
have also been illustrated in the form of histograms in
order to better indicate the level of significance between
treatment groups.
Reverse transcriptase PCR (RT-PCR)
Cells were lysed in TRIzolW reagent to extract total
cellular RNA. Single-stranded cDNA was synthesized
from 5 μg of total RNA using M-MLV Reverse Tran-
scriptase. The sequences of the primers used for PCR
were: VEGF (NM_001025370, 226 bp) 5’-AAGGAGGA
GGGCAGAATCAT-3’ (forward) and 5’-ATCTGCATGG
TGATG TTGGA-3’ (reversed), HIF-1α (NM_001530,
193 bp) 5’-CCATTAGAAAGCAGT TCCGC-3’ (forward)
and 5’-TGGGTAGGAGATGGAGATGC-3’ (reverse).
GAPDH (595 bp) primers with sequence of 5’-CCACCC
ATGGCAAATTCCATGGCA-3’ (forward) and 5’-TCTA
GACGGCAG GTCAGGTCCACC-3’ (reverse) were used
as internal control. Conditions used for PCR consisted
of 30 cycles for VEGF at 95°C for 2 min, 94°C for 30 s,
60°C for 30 s and 72°C for 30 s; 35 cycles for HIF-1α at
95°C for 15 min, 94°C for 45 s, 60°C for 45 s and 72°C
for 45 s with a final incubation at 72°C for 10 min in a
thermal cycler (GeneAmp PCR System 9700, Applied
Biosystems). The RNA products were resolved by elec-
trophoresis on 1.8% TAE agarose gel stained with eth-
idium bromide.Tumor xenograft in nude mice
The experimental procedures were approved by our in-
stitutional “Committee on the Use of Human and Ani-
mal Subjects in Teaching and Research (HASC)” with
reference to the European Community guidelines for the
use of experimental animals. Five-week-old female Balb/
c-nu/nu mice were kept under sterile conditions in iso-
lated pathogen-free ventilation chambers under ambient
temperature of 20-22°C and 45-50% relative humidity.
The animal rearing facility was maintained on a 12 h
light–dark cycle. Mice were given free access to sterile
food and water.
Cell suspension was prepared by trypsinization of con-
fluent HCT 116 cells. Mice were randomly assigned to
the control and AST treatment group. They were
anesthetized with i.p. injection of 75 mg/kg ketamine
and 10 mg/kg xylazine. Cell suspension was injected
subcutaneously into the right thigh of the mice at the
density of 2 × 106 cells (in 100 μl DMEM medium). The
day of tumor implantation was designated as Day 0.
AST (100 mg/kg) was administrated orally once daily for
14 days after the tumors became palpable at Day 10.
This dosage was acquired from our previous study as
the optimal dose to alleviate tumor formation without
causing systemic toxicity [5]. Tumor volume was mea-
sured using a digital caliper every 3 days and calculated
as (length x width2)/2.
Immunohistochemical analysis
Tumors were excised from HCT 116 xenograft mice on
the day of sacrifice (Day 24). The paraffin-embedded
samples were sectioned into 5 μm in thickness and
mounted onto the slides. Slides were deparaffinized in
xylene, followed by rehydration in ethanol. Antigens on
the tumor tissues were retrieved by heating the sections
with 10 mM sodium citrate, pH 6.0. Immunohistochem-
ical analysis was performed by SuperPictureTM 3rd Gen
Detection Kit (Invitrogen, Carlsbad, CA). The endogen-
ous peroxidase activities were blocked by incubating
with hydrogen peroxide. The sections were blocked with
2% bovine serum albumin (BSA) to minimize non-
specific background and then incubated overnight with
anti-COX-2 antibody at 1:200 dilutions (in 0.2% BSA) at
4°C. SuperPictureTM reagent followed by 3,3-diamino-
benzidine (DAB) reagent were incubated according to
the manufacturer’s instruction. The sections were coun-
terstained with Mayer’s hematoxylin. Negative control
was performed with the same procedures without adding
the primary antibody. All slides were evaluated by a
minimum of two observers.
Enzyme-linked immunosorbent assay (ELISA) for VEGF
To quantify levels of VEGF in the serum, blood samples
were collected from HCT 116 xenografted nude mice on
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Samples were centrifuged at 2,000 g for 10 min at 4°C.
The serum was assayed by using a mouse ELISA kit for
detecting VEGF (Calbiochem) according to the manufac-
turer’s instructions (Invitrogen, Carlsbad, CA).
Statistical analysis
All data were presented as mean ± standard error of the
mean (S.E.M.). Statistical significance of at least p < 0.05
was determined by one-way analysis of variance
(ANOVA) followed by a post-hoc Least Significant Dif-
ference (LSD) test using the SPSS version 10.0 software.
Results
AST downregulated the protein expression of angiogenic
factors bFGF and VEGF in vitro
Basic fibroblast growth factor (bFGF) and VEGF are two
key regulators for vasculogenesis secreted from the
tumor cells and contribute synergistically to different
stages of blood vessel formation [28]. Effect of AST on
these two factors was evaluated in HCT 116 colon can-
cer cells. Our results show that AST significantly
reduced the protein expression of both bFGF and VEGF
in a time-dependent manner (Figure 1A). VEGF protein
expression was also downregulated dose-dependently
after AST treatment (Figure 1B). These results indicate
that AST could attenuate the tumor progression through
inhibition of intrinsic angiogenic factors.
Effect of AST on PI3K/Akt/mTOR pathway and MAPK
signaling
PI3K/Akt/mTOR pathway regulates various cellular ac-
tivities. Its activation is associated with tumor progres-
sion including promotion of angiogenesis and invasion,
and enhancement of metastatic potential in several
human cancers, including colon cancer [29,30]. There-
fore, several important signal transduction molecules in
this pathway were examined in the present study, in
which it is well known that PTEN serves as negative
regulator in the PI3K/Akt pathway. Our time-course
study shows that the protein expression of PTEN
increased after 24 h of AST incubation. Activation of
Akt was also studied by the assessment of phosphory-
lated form of Akt (p-Akt) at Ser 473. Results showed
that p-Akt was downregulated after 48 h of AST treat-
ment while no significant change in total Akt protein
was observed. The effect of AST on mTOR which is a
downstream target of Akt, was then investigated. AST
could downregulate the phosphorylated form of mTOR
(p-mTOR) upon 48 h of drug treatment without signifi-
cant change in total mTOR level (Figure 2A).
The effect of AST on MAP kinase signaling, which is
another known upstream pathway attributed to tumor
angiogenesis and invasion [30,31] was also examined.Results show that AST did not cause significant change
on the protein expression of either phosphorylated or
total JNK as well as p38 over the course of study
(Figure 2B). Thus, it appears that AST mainly exerts its
anti-carcinogeneic effect by modulating Akt/mTOR sig-
naling but not JNK or p38 MAP kinase signaling.
Inhibitory effects of the combined treatment of AST and
the inhibitors of PI3K/Akt/mTOR signaling on bFGF and
VEGF level
To further investigate the involvement of PI3K/Akt/
mTOR signaling in the AST-induced anti-angiogenic
effects against colon cancer, HCT 116 cells were treated
with PI3K inhibitor LY294002 (50 μM), Akt inhibitor
(10 μM) or mTOR inhibitor rapamycin (50 nM), re-
spectively. Results show that the protein expression of
bFGF and VEGF was further reduced after co-treatment
of AST and rapamycin for 72 h when compared to either
AST or rapamycin treatment alone (Figure 2C). How-
ever, no further inhibition of these proteins expression
could be observed in the combined treatment of AST
with either LY294002 or Akt inhibitor (unpublished
observations). Thus, the observed additive effect of AST
and rapamycin suggests that the inhibitory action of
AST on these angiogenic factors could at least partly act
through mTOR signaling, but not the entire PI3K/Akt/
mTOR pathway. Further investigation would be carried
out to find out if AST affects individual regulatory mole-
cules in mTOR signaling.
Study of HIF-1α and VEGF expression under CoCl2-
mimicked hypoxic condition
The state of hypoxia is physically existed in tumor mass,
which in turn stimulate angiogenesis to nourish the cells.
Cobalt chloride (II) (100 μM) was added to HCT 116
cells to mimic hypoxic condition. HIF-1α protein ac-
tively undergoes degradation and is almost undetectable
in HCT 116 cells under normoxic condition. Upon the
exposure of CoCl2, the protein level of HIF-1α was ele-
vated in HCT 116 cells and this accumulation of HIF-1α
would transcriptionally upregulate VEGF mRNA level.
CoCl2 does not induce HIF-1α mRNA expression. HIF-
1α protein is continuously degraded under normoxic
conditions by the ubiquitin-proteasome pathway, which
is catalyzed by HIF prolyl hydroxylases. The hydroxy-
lated HIF-1α is then recognized by a von Hippel-Lindau
protein (pVHL). Cobalt mimics hypoxia by inactivating
the hydroxylase activity and preventing the interaction
between HIF-α and pVHL, thereby preventing the deg-
radation of HIF-1α [32]. Our results show that CoCl2
did not affect the mRNA expression of HIF-1α but in-
tensely induce the protein expression in HCT 116 cells,
which is consistent with Fukuda’s findings using the
same cell line [33]. AST treatment alone for 3–6 hours
Figure 1 AST downregulates pro-angiogenic factors in HCT 116 colon cancer cells. (A) HCT 116 cells were treated with AST (80 μg/ml) and
Western blotting was performed to analyze the level of bFGF and VEGF in a 72-hour time course study. (B) Various concentrations of AST (0, 40,
60 or 80 μg/ml) were administered to HCT 116 cells for 24, 48 or 72 h to determine its concentration-dependent effect on bFGF and VEGF level.
Representative immunoblots from at least three independent experiments are shown. Relative band densities were summerized in histograms
after normalization by β-actin. Arbitrary data are expressed as mean ± S.E.M., with statistical significance * p < 0.05, ** p < 0.01 when compared
with the untreated group at 0 h (A) or the respective control group (B).
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and COX-2 (unpublished observations). Our results
show that CoCl2-induced VEGF mRNA expression was
significantly reduced to control level after AST treat-
ment (Figure 3A). Furthermore, the induced protein ex-
pression of both HIF-1α and VEGF was abolished in
AST-treated cells. We next investigated whether mTOR
is involved in such suppression under the mimetic hyp-
oxic condition. Cells were pre-treated with rapamycin
for 30 min prior to the addition of CoCl2. Rapamycin
(50 nM) could reduce the protein expression of HIF-1α
and VEGF at 6 h while co-treatment of AST (80 μg/ml)
showed an additional effect on such drop (Figure 3B).
Based on the above results, it is probable that AST could
act through mTOR signaling to regulate HIF-1α and
VEGF under CoCl2-induced hypoxia.
Effects of AST on the inhibition of COX-2 in colon cancer
cells
Blockade of COX-2 can suppress intestinal polyp forma-
tion and prevent colon carcinogenesis [34]. The role ofCOX-2 in tumor regulation and angiogenesis has been
extensively investigated [17,20,35]. In this part of the
study, HT-29 cells were used instead of HCT 116 cells
because COX-2 is not expressed in the latter cell type
under normoxic condition [18,36]. Our results show that
AST (60 μg/ml) significantly reduced the protein expres-
sion of COX-2 in HT-29 colon cancer cells in a time-
dependent manner under normoxia. The cells were trea-
ted with COX-2 inhibitor indomethacin (100 μM) with
or without the combined treatment with AST. Com-
bined treatment imposed greater inhibition on the pro-
tein expression of COX-2 when compared to individual
drug effects (Figure 4A).
COX-2 was reported to be induced by hypoxia in
colon cancer and was transcriptionally regulated by HIF-
1α [18]. Therefore, the effect of AST on COX-2 inhib-
ition under hypoxic condition had been studied. COX-2
protein expression can be induced in HCT 116 cells
under the condition of CoCl2-mimicked hypoxia. Our
results demonstrate that either AST or indomethacin
(100 μM) alone could suppress CoCl2-induced COX-2
Figure 2 (See legend on next page.)
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Figure 2 AST acts by modulation of PI3K/Akt/mTOR signaling but does not involve the MAPK pathway. HCT 116 cells were treated with
AST (80 μg/ml) and Western blotting was performed to analyze the level of (A) PTEN, p-Akt, Akt, p-mTOR, mTOR and (B) p-JNK, JNK, p-p38 and
p38 in a 72-hour time course study. (C) Combined effects of AST and rapamycin on the pro-angiogenic factors bFGF and VEGF. HCT 116 cells
were incubated with AST (80 μg/ml) either in the absence or presence of the mTOR inhibitor rapamycin for 72 h. Rapamycin (50 nM) was added
30 min prior to the AST treatment. Representative immunoblots from at least three independent experiments are shown. β-actin was used as
internal control in immunoblot assay. Arbitrary data are expressed as mean ± S.E.M., with statistical significance * p < 0.05, ** p < 0.01 when
compared with the untreated group at 0 h (A) or control group (B); + p < 0.05 when compared with rapamycin group.
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downregulation of these parameters was observed with
combined treatment of indomethacin and AST
(Figure 4B). Taken together, we propose that AST could
downregulate VEGF level through inhibition of COX-2
under both normoxic and hypoxic conditions.AST reduced tumor volume in HCT 116-xenografted nude
mice
Mice were orally fed with saline or AST (100 mg/kg)
once daily for 14 consecutive days. No significant change
in body weight and no mortality were observed in all
treatment groups throughout the entire course of the
experiment. Tumor volume was reduced by 42.6%
(552 ± 49.6 mm3 in control versus 317 ± 56.0 mm3 in
AST-treated mice after 14-day drug treatment compared
to saline control (Figure 5A).Figure 3 AST suppresses HIF-1α and VEGF induction under hypoxia in
medium of HCT 116 cells 30 min prior to various drug treatments to mimic
molecule VEGF by CoCl2 over a 24-hour course was monitored in HCT 116
mRNA expression was then assessed. (B) Combined treatment of AST and
under CoCl2-mimicked hypoxic condition in HCT 116 cells. Data represents
GAPDH were used as internal control in immunoblot assay and RT-PCR, res
significance * p < 0.05 when compared with control group; # p < 0.05, ## p
compared with CoCl2 + rapamycin group.AST reduced serum VEGF level in tumor xenograft nude
mice
Angiogenesis is sometimes linked with advanced can-
cers, while blockade of VEGF production significantly
diminishes the tumor volume in vivo [8]. The effect of
AST on VEGF production was therefore investigated by
measurement of the circulating level of VEGF in tumor-
bearing mice. Treatment with AST resulted in a signifi-
cant reduction in serum VEGF level (Figure 5B), provid-
ing an insight of its anti-tumor effect at least partly due
to the inhibition of angiogenesis.AST attenuated angiogenesis in nude mice xenograft
through inhibition of mTOR and COX-2
In HCT 116 xenografted nude mice model, tumors were
excised and Western blotting was performed in tumor
tissues. Our results show that the protein expression ofcolon cancer cells. CoCl2 (100 μM) was added to the culture
hypoxic condition. (A) The induction of HIF-1α and its downstream
cells. The effect of AST (80 μg/ml) on HIF-1α and VEGF protein and
rapamycin (50 nM) suppressed HIF-1α and VEGF protein expression
the mean of at least three independent experiments. β-actin and
pectively. Arbitrary data are expressed as mean ± S.E.M., with statistical
< 0.01 when compared with CoCl2 hypoxia group;
+ p < 0.05 when
Figure 4 AST suppresses COX-2 and VEGF induction under normoxia and hypoxia in colon cancer cells. (A) Effects of AST alone {A}
(60 μg/ml) or in combined treatment with indomethacin {A + I} on the level of COX-2 in HT-29 cells under normoxia. (B) Combined treatment of
AST (80 μg/ml) and indomethacin (100 μM) suppressed the induced COX-2 and VEGF level under CoCl2-mimicked hypoxic condition in HCT 116
cells. Data represents the mean of at least three independent experiments. β-actin was used as internal control in immunoblot assay. Arbitrary
data are expressed as mean ± S.E.M., with statistical significance * p < 0.05, ** p < 0.01 when compared with the untreated group at 0 h or
control group; # p < 0.05, ## p < 0.01 when compared with CoCl2 hypoxia group;
+ p < 0.05 when compared with indomethacin (A) or
CoCl2 + indomethacin (B) group.
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downregulated in AST-treated mice compared to that of
control (Figure 5D). Similarly, p-Akt and p-mTOR level
was also decreased after AST treatment (Figure 5C).
Moreover, AST could inhibit COX-2 expression in the
tumor section from nude mice xenograft (Figure 5E). All
these findings re-confirm the in vitro results about the
inhibitory effects of AST on tumor angiogenesis that are
regulated by modulation of both mTOR and COX-2 sig-
naling in colon cancer cells.
Discussion
Angiogenesis is essential for tumor progression because
tumor mass cannot grow bigger than 2 mm3 without the
nourishment of blood vessels. Moreover, vascularization
is required for the process of extravasation in metastasis
[7]. Hence, establishment of chemotherapeutic strategy
by blocking angiogenesis attracts much attention in re-
cent years. Besides, alteration of the cellular adaptation
to hypoxia is also fundamental in cancer treatmentbecause angiogenesis or other metabolic modifications
will be stimulated to maintain tumor cell survival [37].
Our ongoing study revealed that AST could significantly
reduce tumor growth in nude mice by inhibiting cell pro-
liferation and promoting apoptosis. We then hypothe-
sized that AST may also attenuate tumor angiogenesis
both in vitro and in vivo. VEGF is the most potent pro-
angiogenic factor to facilitate tumor angiogenesis. Block-
ade of VEGF production significantly inhibited tumor
growth in various mice models [8-10]. In the present
study, we have demonstrated that AST could reduce
tumor volume in HCT 116 nude mice xenograft with a
concomitant decrease in serum VEGF level, suggesting
that AST exerts its anti-tumor effect in colon cancer by
targeting VEGF and its associated signaling pathways.
PI3K/Akt kinase cascade is one of the most import-
ant signaling pathways in cancer development, which
correlates strongly with angiogenesis, invasiveness and
metastasis of the tumor. Our results have shown that
AST significantly reduced protein expression of the
Figure 5 AST inhibits tumor growth and suppresses tissue VEGF level by modulating Akt/mTOR signaling and COX-2. HCT 116 colon
cancer cells (2 × 106) were injected subcutaneously to the Balb/c nu/nu mice. AST (100 mg/kg) was administrated orally once daily for 14 days
after the tumors became palpable at Day 10. Tumors from the xenografted mice were excised at the day of sacrifice. (A) Tumor volume and (B)
serum VEGF level in the control and AST-treated groups of animals were measured. Data are expressed as mean ± S.E.M. (n = 6), with statistical
significance * p < 0.05, ** p < 0.01 when compared with control group. (C) Tissue level of p-Akt, Akt, p-mTOR, mTOR, and (D) the pro-angiogenic
factors VEGF, VEGFR1 and VEGFR2 was examined in untreated control (#1-2) and AST-treated (#3-4) groups of animals. Representative
immunoblots from tumor tissues obtained from six animals in each group are shown. β-actin was used as internal control in immunoblot assay.
(E) Histological examination of COX-2 level in tissue sections of HCT 116 xenografted nude mice with or without AST treatment was performed.
Representative microphotographs of control and drug-treated groups are shown (200x magnification).
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reported that AST exhibited antitumorigenic and proa-
poptotic actions in HCT 116 cells through induction of a
novel proapoptotic protein NAG-1, which could be in-
tensified by the co-treatment of PI3K-Akt inhibitors [4].
Based on this background, the transcriptional factors
involved in PI3K/Akt signaling were further examined in
the present study. Data from our in vitro experiments
show that AST caused upregulation of the tumor sup-
pressor PTEN, inhibition of Akt phosphorylation at Ser
473 as well as downregulation of p-mTOR. These find-
ings implicate the possible involvement of PI3K/Akt/
mTOR signaling in the anti-carcinogenic action of AST.
To confirm whether such regulation is related to the
anti-angiogenic effect, cells were treated with the com-
bination of either LY294002, Akt inhibitor or rapamycin
with AST. Neither LY294002 or Akt inhibitor alone
reduced the level of bFGF and VEGF, while co-treatment
with AST did not lead to additional effect (unpublished
observations). In contrast, rapamycin alone induced sig-
nificant downregulation of these growth factors, while agreater inhibitory effect was achieved with combined
treatment of rapamycin and AST. Based on these obser-
vations, PI3K and Akt are less likely to be the target
molecules of AST responsible for its downregulation of
the two angiogenic factors. Alternatively, it has been
known that activation of MAPK signaling pathway may
also be involved in promoting tumor angiogenesis and
invasion [30,31]. We have shown that AST could not
cause significant activation of JNK and p38 MAP kinase.
Although our previous study have indicated that ERK1/2
activity was increased within 6 h following AST treat-
ment, and that this transient induction could be related
to its proapoptotic function involving Egr-1 induction
[5,38], no evidence has indicated a direct correlation with
angiogenesis in this study. From the above information,
we propose that AST could suppress the angiogenic fac-
tors through inhibition of mTOR signaling rather than
via modulation of the MAPK pathway.
VEGF is transcriptionally regulated by HIF-1α, result-
ing in overexpression in human colon cancer biopsies.
Moreover, forced induction of HIF-1α in HCT 116 cells
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[39]. Physiological stimulus such as hypoxia can inhibit
the degradation of the HIF-1α subunit, and then the ac-
cumulation of HIF-1α dimerizes with the constitutively
expressed HIF-1β subunit and activates the transcription
and stabilization of VEGF gene [40]. Stabilization of
HIF-1α can be also induced by transition metals such as
cobalt, nickel, and manganese, by iron chelators and by
antioxidants. These metallic ions mimic hypoxia by
binding to the heme portion of oxygen-sensing mole-
cules inside the cells [41]. CoCl2, being a common
hypoxic-mimetic agent, was used to investigate the effect
of AST on the expression of HIF-1α and VEGF under
hypoxic condition. CoCl2 did not affect the mRNA ex-
pression of HIF-1α but intensely induce HIF-1α protein
expression in HCT 116 cells. AST could significantly re-
duce the CoCl2-induced HIF-1α protein expression and
VEGF mRNA expression under the mimetic hypoxic
condition. At present, it remains unclear whether it is
the degradation rate or the protein synthesis of HIF-1α
that has been reduced by AST [33,40], which requires
further investigation. Following this, the effect of com-
bined rapamycin and AST treatment under the mimetic
hypoxic condition was also investigated. An even greater
downregulation of HIF-1α and VEGF expression was
achieved in the combined treatment when compared to
the effects of either agent alone. mTOR was found to be
an upstream activator of HIF-1α expression in cancer
cells [25]. Direct interaction between these two proteins
may exist since there has been evidence showing that
HIF-1α activity during hypoxia requires an mTOR sig-
naling motif located at the N terminus of HIF-1α, while
high level of HIF activity can be reversed by rapamycin
[42]. Based on the above interrelationship, we suggest
that AST could suppress tumor angiogenesis by interfer-
ing with the mTOR/HIF-1α axis under CoCl2-stimulated
hypoxia.
COX-2 expression has been found to be upregulated
in most human tumors including colon, lung, breast and
prostate, which also attributes to cancer-related inflam-
mation, tumor cell proliferation, resistance to apoptosis
and angiogenesis [43]. Evidence has shown that HIF-1
directly binds to a specific HRE on the COX-2 promoter
in such a way that COX-2 serves as a HIF-1 target gene
and is induced during hypoxia [18]. The same report
also mentions that COX-1 expression would remain un-
changed in colon cancer cells under hypoxia, suggesting
the significance of the COX-2 isozyme alone in the regu-
lation of the hypoxia-adaptive response [44]. As men-
tioned earlier, AST could downregulate VEGF expression
through mTOR signaling. Nonetheless, since the expres-
sion of VEGF was not completely inhibited by rapamy-
cin in HCT 116 cells, other signaling pathways may also
be involved in the regulation of VEGF, including theCOX-2 cascade. Under hypoxia, COX-2 can trigger
VEGF induction and the response is independent of the
COX-2 cellular level [45]. HCT 116 cells are natively
COX-2-negative, whereas another colon cancer cell line
HT-29 has high constitutive COX-2 level. Thus, HT-29
cells had been chosen to determine the effect of AST on
COX-2 expression under normoxic condition. AST sig-
nificantly decreased constitutive protein expression of
COX-2 in HT-29 cells. On the other hand, COX-2 ex-
pression could be eminently induced in COX-2-deficient
HCT 116 cells by CoCl2. We found that protein expres-
sion of both COX-2 and VEGF would be reduced fol-
lowing 24 h of AST treatment, with further decrease
when indomethacin was co-treated. This implicates that
AST could have inhibited VEGF expression through
downregulation of COX-2 under hypoxia. Further inves-
tigation could be established to explore the direct effect
of AST on the generation of COX-2 products such as
prostaglandins and thromboxanes, since their increased
production has been reported to induce VEGF secretion
from tumor cells [46].
In the HCT 116-xenografted nude mice model, daily
intake of AST markedly reduced the tumor volume of
the mice when compared to the control animals. Results
show that the decrease of VEGF expression in tumor tis-
sue of AST-treated mice was correlated with the down-
regulation of p-Akt, p-mTOR and COX-2, which are
consistent with the in vitro findings. VEGFR-1 and
VEGFR-2 are receptors distinctively present on vascular
endothelial cells, which have strong association with cell
proliferation, migration and induction of vascular per-
meability [47]. VEGFR-1 was found in colorectal cell
lines including HCT 116 to promote cell migration and
invasion [48]. Thus, the decreased expression of both
VEGFR-1 and VEGFR-2 in tumor tissues suggests that
AST could attenuate tumor progression via inhibition of
angiogenesis and metastasis [49]. As a matter of fact,
there is a close relationship between matrix metallopro-
teinases (MMPs) and VEGF in tumor progression, of
which MMP-9 induces the release of biologically active
VEGF in the culture of ovarian tumor cells and in ascites
of ovarian tumor-bearing mice [50]. MMPs are secreted
by recruited macrcophages, mast cells and fibroblasts, of
which one important role of MMPs is to degrade and re-
model the surrounding extracellular matrix (ECM) by
proteolysis. When ECM is degraded, angiogenic factors
being sequestered there in addition to cytokines and
tumor cells will be released together, further facilitating
the growth and infiltration of new blood vessels into the
tumor [51]. We have previously discovered that AST
could downregulate MMPs and other factors associated
with ECM degradation together with its modulation of
tissue VEGF level (unpublished observations). The corre-
lated interactions between VEGF, MMPs and other
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activator (uPA) as well as their potential regulation by
AST during control of tumor progression still needs to
be elucidated in the near future.
Conclusions
To summerize, we conclude that AST is able to attenu-
ate tumor growth by downregulation of VEGF produc-
tion, which involves modulation of mTOR and COX-2
signaling. The inhibition of COX-2 may also ameliorate
the inflammatory responses that could be associated
with further cancer development [23]. In the present
study, AST was found to have multiple molecular tar-
gets, while its mode of action involves robust synergistic
interaction with other novel tumor markers and modula-
tors as implicated from our previous works [4,5]. All
these evidences suggest that AST is a potential candidate
for further development as an adjuvant in modern che-
motherapeutic treatment of colon cancer, perhaps to
work together with other effective agents such as bevaci-
zumab to further boost the anti-cancer effects of each
other.
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